Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of AdCLD-CoV19 in Healthy Volunteers
NCT04666012Phase 2Completed
- Sponsor
- Cellid Co., Ltd.
- Start
- Dec 2020
- Primary completion
- Jul 2021
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of AdCLD-CoV19 in coronavirus disease 2019 (COVID-19), sponsored by Cellid Co., Ltd.. Started Dec 2020; status: completed.
02
Drugs
AdCLD-CoV19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04666012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04666012.